Search research articles
Contact Us
Filters
Showing results (341-350 of 358) with videos related to
Page
of 36
Sort By:
The Lancet Regional Health. Europe
|
August 7, 2023
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
|
October 16, 2023
Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people
Claudio Babiloni, Claudio Del Percio, Claudia Piervincenzi, et al.
Antiviral Therapy
|
April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen
Daniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Retrovirology
|
June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study
Stefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Antiviral Therapy
|
January 25, 2013
Impact of pre-therapy viral load on virological response to modern first-line HAART
Maria Mercedes Santoro, Daniele Armenia, Claudia Alteri, et al.
Clinical and Experimental Rheumatology
|
May 3, 2020
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
Savino Sciascia, Franco Aprà, Alessandra Baffa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 25, 2016
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program
Andreoni Massimo, Elisabetta Teti, Andrea Antinori, et al.
Retrovirology
|
May 1, 2015
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
Fabrizio Ensoli, Aurelio Cafaro, Anna Casabianca, et al.
Plos One
|
February 21, 2018
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
Lucia Taramasso, Antonio Di Biagio, Francesca Bovis, et al.
Page
of 36
Search research articles
Search
Showing results (341-350 of 358) with videos related to
Sort By:
Page
of 36
The Lancet Regional Health. Europe
|
August 7, 2023
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
|
October 16, 2023
Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people
Claudio Babiloni, Claudio Del Percio, Claudia Piervincenzi, et al.
Antiviral Therapy
|
April 13, 2019
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen
Daniele Armenia, Domenico Di Carlo, Alessandro Cozzi-Lepri, et al.
Retrovirology
|
June 26, 2014
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study
Stefania Bellino, Antonella Tripiciano, Orietta Picconi, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
Antiviral Therapy
|
January 25, 2013
Impact of pre-therapy viral load on virological response to modern first-line HAART
Maria Mercedes Santoro, Daniele Armenia, Claudia Alteri, et al.
Clinical and Experimental Rheumatology
|
May 3, 2020
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19
Savino Sciascia, Franco Aprà, Alessandra Baffa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 25, 2016
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program
Andreoni Massimo, Elisabetta Teti, Andrea Antinori, et al.
Retrovirology
|
May 1, 2015
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
Fabrizio Ensoli, Aurelio Cafaro, Anna Casabianca, et al.
Plos One
|
February 21, 2018
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
Lucia Taramasso, Antonio Di Biagio, Francesca Bovis, et al.
Page
of 36